SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    James R. Burton, Jacqueline G. O’Leary, Elizabeth C. Verna, Varun Saxena, Jennifer L. Dodge, Richard T. Stravitz, Joshua Levitsky, James F. Trotter, Gregory T. Everson, Robert S. Brown, Norah A. Terrault, A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy, Journal of Hepatology, 2014,

    CrossRef

  2. 2
    Sammy Saab, Vignan Manne, Sherona Bau, Justin A. Reynolds, Ruby Allen, Leonard Goldstein, Francisco Durazo, Mohammed El-Kabany, Steven Han, Ronald W. Busuttil, Boceprevir in liver transplant recipients, Liver International, 2014, 34, 6
  3. 3
    Sarah Tischer, Robert J. Fontana, Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting, Journal of Hepatology, 2014, 60, 4, 872

    CrossRef

  4. 4
    EASL Clinical Practice Guidelines: Management of hepatitis C virus infection, Journal of Hepatology, 2014, 60, 2, 392

    CrossRef

  5. 5
    Jesús Ruiz Ramos, Irene Romero Hernández, Patricia Marrero Álvarez, María Remedios Marqués Miñana, María José Fernández Megía, José Luis Poveda Andrés, Experiencia en el manejo de inmunosupresores con los fármacos inhibidores de proteasa frente al virus de la hepatitis C, Gastroenterología y Hepatología, 2014,

    CrossRef

  6. 6
    J. Howell, P. Angus, P. Gow, Hepatitis C recurrence: the Achilles heel of liver transplantation, Transplant Infectious Disease, 2014, 16, 1
  7. 7
    Elizabeth C. Verna, Hepatitis Viruses and Liver Transplantation, Clinics in Liver Disease, 2014, 18, 3, 575

    CrossRef

  8. You have free access to this content8
    Audrey Coilly, Bruno Roche, Jean-Charles Duclos-Vallée, Didier Samuel, Management of HCV transplant patients with triple therapy, Liver International, 2014, 34,
  9. 9
    Sabela Lens, Ignacio Alfaro, Perspectivas futuras del tratamiento de la hepatitis C, ¿sin interferón y sin ribavirina?, Gastroenterología y Hepatología, 2014, 37, 5, 311

    CrossRef

  10. 10
    Audrey Coilly, Bruno Roche, Jérôme Dumortier, Vincent Leroy, Danielle Botta-Fridlund, Sylvie Radenne, Georges-Philippe Pageaux, Si-Nafaa Si-Ahmed, Olivier Guillaud, Teresa Maria Antonini, Stéphanie Haïm-Boukobza, Anne-Marie Roque-Afonso, Didier Samuel, Jean-Charles Duclos-Vallée, Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: A multicenter experience, Journal of Hepatology, 2014, 60, 1, 78

    CrossRef

  11. 11
    Harald Farnik, Tim Zimmermann, Eva Herrmann, Wolf O. Bechstein, Bernd Kronenberger, Peter R. Galle, Sandra Labocha, Nerea Ferreiros, Gerd Geisslinger, Stefan Zeuzem, Christoph Sarrazin, Martin W. Welker, Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation, Liver International, 2014, 34, 6
  12. 12
    Rodrigo Antonio Parra Teixeira, Kallyne Kioko Oliveira Mimura, Leandro Pires Araujo, Karin Vicente Greco, Sonia Maria Oliani, The essential role of annexin A1 mimetic peptide in the skin allograft survival, Journal of Tissue Engineering and Regenerative Medicine, 2014, 8,
  13. 13
    Barbara Coco, Paolo Caraceni, Alessio Aghemo, Davide Bitetto, Raffaele Bruno, Alessia Ciancio, Marco Marzioni, Salvatore Petta, Maria Rendina, Luca Valenti, Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF), Digestive and Liver Disease, 2014, 46, 1, 18

    CrossRef

  14. 14
    Michael Charlton, Travis Dick, Victory and defeat at Heraclea – Treating hepatitis C infection following liver transplantation with telaprevir and boceprevir, Journal of Hepatology, 2014, 60, 1, 6

    CrossRef

  15. 15
    S. Ciesek, M.P. Manns, K. Wursthorn, Aktueller Stand der Lebertransplantation, Der Gastroenterologe, 2013, 8, 1, 35

    CrossRef

  16. 16
    Delphine Degre, Isabelle Colle, Hans Vlierberghe, Christophe Moreno, Boceprevir-based triple therapy for belgian liver transplant patients infected with hepatitis C virus: A preliminary experience, Liver Transplantation, 2013, 19, 6
  17. You have free access to this content17
    Audrey Coilly, Bruno Roche, Didier Samuel, Current management and perspectives for HCV recurrence after liver transplantation, Liver International, 2013, 33,
  18. 18
    S. Mauss, H. Klinker, Drug-Drug Interactions in the Treatment of HCV Among People Who Inject Drugs, Clinical Infectious Diseases, 2013, 57, suppl 2, S125

    CrossRef

  19. 19
    Jennifer J. Kiser, James R. Burton, Gregory T. Everson, Drug–drug interactions during antiviral therapy for chronic hepatitis C, Nature Reviews Gastroenterology & Hepatology, 2013, 10, 10, 596

    CrossRef

  20. 20
    Jacqueline G. O'Leary, Gregory J. McKenna, Göran B. Klintmalm, Gary L. Davis, Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients, Liver Transplantation, 2013, 19, 4
  21. 21
    Neehar D. Parikh, Josh Levitsky, Hepatotoxicity and Drug Interactions in Liver Transplant Candidates and Recipients, Clinics in Liver Disease, 2013, 17, 4, 737

    CrossRef

  22. 22
    E. A. Blumberg, C. C. Rogers, Human Immunodeficiency Virus in Solid Organ Transplantation, American Journal of Transplantation, 2013, 13, s4
  23. 23
    Juan Berenguer Berenguer, Juan González-García, Interacciones farmacocinéticas de telaprevir con otros fármacos, Enfermedades Infecciosas y Microbiología Clínica, 2013, 31, 37

    CrossRef

  24. 24
    J. Trofe-Clark, T.L. Lemonovich, Interactions Between Anti-Infective Agents and Immunosuppressants in Solid Organ Transplantation, American Journal of Transplantation, 2013, 13, s4
  25. 25
    James R. Burton, Gregory T. Everson, Management of the Transplant Recipient with Chronic Hepatitis C, Clinics in Liver Disease, 2013, 17, 1, 73

    CrossRef

  26. 26
    Surakit Pungpapong, Bashar A. Aqel, Ludi Koning, Jennifer L. Murphy, Tanisha M. Henry, Kristen L. Ryland, Maria L. Yataco, Raj Satyanarayana, Barry G. Rosser, Hugo E. Vargas, Michael R. Charlton, Andrew P. Keaveny, Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation, Liver Transplantation, 2013, 19, 7
  27. You have free access to this content27
    Benjamin Maasoumy, Michael P. Manns, Optimal treatment with boceprevir for chronic HCV infection, Liver International, 2013, 33,
  28. 28
    Maria-Carlota Londoño, Gonzalo Crespo, Xavier Forns, Pretransplant and posttransplant treatment of hepatitis C virus infection with protease inhibitors, Current Opinion in Organ Transplantation, 2013, 18, 3, 271

    CrossRef

  29. 29
    Jennifer C. Price, Prevention and Treatment of Recurrent Hepatitis C after Liver Transplantation, Current Hepatitis Reports, 2013, 12, 4, 227

    CrossRef

  30. 30
    R. J. Fontana, E. A. Hughes, M. Bifano, H. Appelman, D. Dimitrova, R. Hindes, W. T. Symonds, Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C, American Journal of Transplantation, 2013, 13, 6
  31. 31
    David Back, Laura Else, The importance of drug–drug interactions in the DAA era, Digestive and Liver Disease, 2013, 45, S343

    CrossRef

  32. 32
    Paul M. Trembling, Sudeep Tanwar, William M. Rosenberg, Geoffrey M. Dusheiko, Treatment decisions and contemporary versus pending treatments for hepatitis C, Nature Reviews Gastroenterology & Hepatology, 2013, 10, 12, 713

    CrossRef

  33. You have free access to this content33
    K. Rajender Reddy, Gregory T. Everson, Treatment of chronic hepatitis C with protease inhibitor-based therapy after liver transplantation, Hepatology, 2013, 58, 3
  34. 34
    Norah Terrault, Liver transplantation in the setting of chronic HCV, Best Practice & Research Clinical Gastroenterology, 2012, 26, 4, 531

    CrossRef

  35. 35
    Geoffrey W. McCaughan, New therapies against HCV: Expected risks and challenges associated with their use in the liver transplant setting, Journal of Hepatology, 2012, 57, 6, 1361

    CrossRef